Regeneron Pharmaceuticals Inc (REGN)
890.68
-15.86
(-1.75%)
USD |
NASDAQ |
Apr 25, 16:00
888.68
-2.00
(-0.22%)
After-Hours: 05:52
Regeneron Pharmaceuticals Revenue (TTM): 13.12B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.12B |
| September 30, 2023 | 13.10B |
| June 30, 2023 | 12.67B |
| March 31, 2023 | 12.37B |
| December 31, 2022 | 12.17B |
| September 30, 2022 | 13.71B |
| June 30, 2022 | 14.23B |
| March 31, 2022 | 16.51B |
| December 31, 2021 | 16.07B |
| September 30, 2021 | 13.54B |
| June 30, 2021 | 12.38B |
| March 31, 2021 | 9.198B |
| December 31, 2020 | 8.497B |
| September 30, 2020 | 7.938B |
| June 30, 2020 | 7.387B |
| March 31, 2020 | 7.013B |
| December 31, 2019 | 6.558B |
| September 30, 2019 | 5.057B |
| June 30, 2019 | 4.976B |
| March 31, 2019 | 5.007B |
| December 31, 2018 | 5.146B |
| September 30, 2018 | 6.365B |
| June 30, 2018 | 6.203B |
| March 31, 2018 | 6.065B |
| December 31, 2017 | 5.872B |
| Date | Value |
|---|---|
| September 30, 2017 | 5.517B |
| June 30, 2017 | 5.236B |
| March 31, 2017 | 4.979B |
| December 31, 2016 | 4.860B |
| September 30, 2016 | 4.732B |
| June 30, 2016 | 4.649B |
| March 31, 2016 | 4.435B |
| December 31, 2015 | 4.104B |
| September 30, 2015 | 3.808B |
| June 30, 2015 | 3.396B |
| March 31, 2015 | 3.063B |
| December 31, 2014 | 2.820B |
| September 30, 2014 | 2.628B |
| June 30, 2014 | 2.499B |
| March 31, 2014 | 2.291B |
| December 31, 2013 | 2.105B |
| September 30, 2013 | 1.909B |
| June 30, 2013 | 1.740B |
| March 31, 2013 | 1.586B |
| December 31, 2012 | 1.378B |
| September 30, 2012 | 1.087B |
| June 30, 2012 | 762.00M |
| March 31, 2012 | 565.41M |
| December 31, 2011 | 445.82M |
| September 30, 2011 | 456.52M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
4.976B
Minimum
Jun 2019
16.51B
Maximum
Mar 2022
10.87B
Average
12.37B
Median
Mar 2023
Revenue (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 9.869B |
| Eli Lilly and Co | 34.12B |
| AbbVie Inc | 54.32B |
| Amgen Inc | 28.19B |
| Pfizer Inc | 58.50B |